Board Appointment

Plethora Solutions Holdings PLC

("Plethora" or the "Company")

Board Appointment

Plethora Solutions Holdings plc (AIM: PLE) announces that Mr Anthony Baillieu has been appointed to the Board as a Non-Executive Director with immediate effect and Mike Collis, Chief Financial Officer, will leave the Board on 31 May 2015 to pursue other opportunities.

Colin Kunz has been appointed as Chief Financial Officer to the Company but will not fulfil a Board position. Colin is an MBA qualified Chartered Accountant with extensive experience as a Finance Director in both private and AIM quoted companies. In the past 7 years Colin has served as Finance Director to Rhead Group, Benson Group and Mediwatch plc (a formerly AIM quoted company). Mike Collis will work with Colin to effect an orderly handover and will continue to work with the Company on a consultancy basis from 1 June 2015.

Anthony has had a long career in insurance, stock broking and asset management in the UK and internationally. Before its sale in 1991 Anthony was a partner of Roach Tilley Grice, an Australian stockbroking firm, with responsibilities for Asia and the Middle East. In 1992 he established Anthony Baillieu and Associates (Hong Kong) Ltd, a specialist financial services recruitment company.

Commenting, Jim Mellon, Chairman of Plethora, said:

"I am delighted to welcome Anthony to the Board. He has significant public markets experience which will further strengthen the Plethora Board. I would also like to thank Mike for his vital contributions to Plethora and wish him well in his future endeavours"

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies:

Mr Anthony Robert Baillieu, age 59

Current Directorships / Partnerships:

Discover Asia Investments Ltd

Discover Europe Investments Ltd

Previous Directorships / Partnerships (held in the past five years)

Black Fire Minerals Ltd

Triton Minerals Ltd

Mr Baillieu does not currently hold any ordinary shares in the Company. There are no other disclosures required in relation to Rule 17 or paragraph (g) of Schedule 2 of the AIM Rules for Companies.

About Plethora

Plethora is headquartered in the UK and is listed on the London Stock Exchange (AIM: PLE LN). Further information is available atwww.plethorasolutions.co.uk 

Plethora is focused on commercializing PSD502™ for the treatment of premature ejaculation with strategic marketing partners and obtaining NDA approval for PSD502™ with the FDA.